EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

The prognostic impact of CDKN2A/B hemizygous deletions in meningioma

Franziska M Ippen iD, Thomas Hielscher, Areeba Patel, Dennis Friedel iD, Kirsten Göbel, Philipp Sievers iD, Till Acker, Matija Snuderl, Sebastian Brandner, Michael Weller iD, Matthias Preusser, Sybren L N Maas und 5 weitere

Neuro-Oncology · 01.05.2026 · 28 (5) · 1209-1219

DOI: 10.1093/neuonc/noag024 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neuro-Oncology, online erschienen am 11.02.2026. Verfasst von Franziska M Ippen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p15, Meningioma, Cyclin-Dependent Kinase Inhibitor p16, Meningeal Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Center for Tumor Diseases, Clinical Neuroscience and is funded by the Emmy-Noether Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meningiomas are the most common adult brain tumors. While homozygous deletions of CDKN2A/B are linked to early recurrence and hence serve as CNS WHO grade 3 criterion, the clinical impact of hemizygous deletions remains unclear—especially since distinguishing between hemi- and homozygous losses can be technically challenging.

Methods

DNA methylation data, copy-number, and mutation data were evaluated on a multicenter cohort of 970 meningiomas. Each sample’s CDKN2A/B status was manually classified by visual inspection in relation to whole chromosomal losses and gains in the copy number profile generated from global methylation array data in relation to other copy number events. Progression probabilities were determined using the Kaplan-Meier method.

Results

Among 970 meningiomas, n = 30 had homozygous, n = 114 hemizygous (n = 31 segmental; n = 83 focal), and n = 826 CDKN2A/B balanced status. In cases with hemizygous deletions in general, an association with increased progression risk compared to balanced cases was observed, although this did not reach statistical significance (log-rank P = .074; HR = 1.36, 95% CI [0.97, 1.90]; P = .07). However, segmental hemizygous losses were linked to a significantly worse prognosis (log-rank P = .0023), but focal hemizygous deletions were not (log-rank P = .523). Segmental hemizygous CDKN2A/B deletions were more frequently associated with a higher amount of high-risk copy number variations than focal losses.

Conclusion

Our findings suggest that hemizygous CDKN2A/B deletions overall do not confer worse risks for progression in meningiomas. The signal for segmental deletions may not be locus-specific but just one representation of the generally instable genome of aggressive meningiomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase Inhibitor p15MeningiomaCyclin-Dependent Kinase Inhibitor p16Meningeal NeoplasmsGene DeletionBiomarkers, TumorHumansFemalePrognosisMaleMiddle AgedDNA MethylationAgedDNA Copy Number VariationsAdultFollow-Up StudiesSurvival Rate

Stichwörter der Autor:innen

CDKN2A/Bhemizygous deletionmeningiomaprogression-free survival

Substanzen

Cyclin-Dependent Kinase Inhibitor p15Cyclin-Dependent Kinase Inhibitor p16CDKN2B protein, humanCDKN2A protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
  • Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Germany.
  • Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Faculty of Bioscience, Heidelberg University, Heidelberg, Germany.

ORCID-Profile: Franziska M Ippen, Dennis Friedel, Philipp Sievers, Michael Weller, Wolfgang Wick, Felix Sahm

Förderung

  • National Center for Tumor Diseases
  • Clinical Neuroscience and is funded by the Emmy-Noether Programme

Zitieren

APA

Ippen, F. M., Hielscher, T., Patel, A., Friedel, D., Göbel, K., Sievers, P., Acker, T., Snuderl, M., Brandner, S., Weller, M., Preusser, M., Maas, S. L. N., Deimling, A. V., Wick, W., Bi, W. L., Sahm, F., & Suwala, A. K. (2026). The prognostic impact of CDKN2A/B hemizygous deletions in meningioma. Neuro-Oncology, 28(5), 1209-1219. https://doi.org/10.1093/neuonc/noag024

Vancouver

Ippen FM, Hielscher T, Patel A, Friedel D, Göbel K, Sievers P, et al. The prognostic impact of CDKN2A/B hemizygous deletions in meningioma. Neuro-Oncology. 2026;28(5):1209-1219. doi:10.1093/neuonc/noag024

BibTeX
@article{Ippen2026,
  author = {Ippen, Franziska M and Hielscher, Thomas and Patel, Areeba and Friedel, Dennis and Göbel, Kirsten and Sievers, Philipp and Acker, Till and Snuderl, Matija and Brandner, Sebastian and Weller, Michael and Preusser, Matthias and Maas, Sybren L N and Deimling, Andreas V and Wick, Wolfgang and Bi, Wenya Linda and Sahm, Felix and Suwala, Abigail K},
  title = {The prognostic impact of CDKN2A/B hemizygous deletions in meningioma},
  journal = {Neuro-Oncology},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {1209--1219},
  doi = {10.1093/neuonc/noag024}
}
Kostenlos starten →